ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
ReShape Announces Positive Preclinical Results for Diabetes Neuromodulation Device americanpharmaceuticalreview
September 17, 2020ReShape Lifesciences announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation? (DBSN?) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study ... -
ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes
biospace
April 11, 2018?ReShape Lifesciences?Inc. announced today that the Company will be presenting early results of a new, novel use of the ReShape Lifesciences? neuro-blocking technology in combination with separate-site vagus nerve stimulation for the treatment of type 2
Pharma Sources Insight January 2025
